RxDoctor Payments Data

Christina Hazime, NP

Primary Care · Dearborn, MINPI 1245982909

Payments from drug & device makers

$1,137in general payments, 2019–2025

Across 63 payments — averaging $18.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$463
  • GSK$244
  • Alkermes, Inc.$199
  • USWM, LLC$106
  • AstraZeneca$44
  • Lilly USA, LLC$35
  • plus $46 from 2 others

What the payments were for

  • Food & beverage$1,137100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk42$463
GSK10$244
Alkermes, Inc.2$199
USWM, LLC3$106
AstraZeneca2$44
Lilly USA, LLC2$35
Exact Sciences1$25
Novartis1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,137 in reported general payments places this provider in the 70th percentile of 292 primary care providers in Michigan.

See all primary care providers in Michigan

Medicare billing

Part B allowed, 2024
$13,717
Medicare patients
88
Services billed
217

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate27$18,303
OzempicSemaglutide19$18,092
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl180$17,435
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$11,433
LinzessLinaclotide20$10,334
FarxigaDapagliflozin Propanediol17$9,674
EliquisApixaban16$9,316
ZubsolvBuprenorphine Hcl/Naloxone Hcl12$5,563
Albuterol Sulfate HfaAlbuterol Sulfate88$2,673
Esomeprazole Magnesium37$2,011
Fluticasone-SalmeterolFluticasone Propion/Salmeterol19$1,789
Alcohol Prep PadsAlcohol Antiseptic Pads18$833
Fluticasone Propionate71$677
Diclofenac Sodium39$655
Omeprazole73$632

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$463$18,09219 claims
GSKTrelegy Ellipta$244$11,43318 claims
AstraZenecaFarxiga$44$9,67417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 292 primary care providers in Michigan.

Other primary care in Dearborn

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →